Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variations in the thrombin-activatable fibrinolysis inhibitor gene and risk of cardiovascular disease: a systematic review and meta-analysis.

Thrombosis research - 1 Sept 2014

Shi Jian, Zhi Pengke, Chen Jian, Wu Peihua, Tan Sheng

Abstract excerpt

BACKGROUND: An imbalance between coagulation and fibrinolytic system plays an important role in the pathogenesis of arterial thrombosis. It has been identified that elevated plasma thrombin-activatable fibrinolysis inhibitor (TAFI) concentration, an anti-fibrinolytic factor, is associated with an increased risk of cardiovascular disease (CVD). But the effect of genetic variations in TAFI gene on the risk of CVD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carboxypeptidase B2
Share to Cardiovascular Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Odds Ratio

Share to Phenotype

Share to Polymorphism, Genetic

Share to Risk Assessment

Share to Risk Factors

Source

Identifiers

PMID: 25042727
DOI: 10.1016/j.thromres.2014.06.023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variations in the thrombin-activatable fibrinolysis inhibitor gene and risk of cardiovascular disease: a systematic review and meta-analysis.PMID 25042727Read ↗

Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study.Semantic proximity Read ↗

Association between thrombin-activatable fibrinolysis inhibitor gene polymorphisms and venous thrombosis risk: a meta-analysis.Semantic proximity Read ↗

Genetic Polymorphisms Associated with Thrombotic Disease Comparison of Two Territories: Myocardial Infarction and Ischemic Stroke.Semantic proximity Read ↗

The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study.Semantic proximity Read ↗

Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients.Semantic proximity Read ↗

Meta-analysis of TAFI polymorphisms and risk of cardiovascular and cerebrovascular diseases.Semantic proximity Read ↗

Impact of genetic polymorphisms in thrombin activatable fibrinolysis inhibitor (TAFI) on venous thrombosis disease: A meta-analysis.Semantic proximity Read ↗

Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects.Semantic proximity Read ↗

Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome.Semantic proximity Read ↗

Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.Semantic proximity Read ↗

TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study.Semantic proximity Read ↗

The factor XII -4C>T variant and risk of common thrombotic disorders: A HuGE review and meta-analysis of evidence from observational studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.